JP2014524480A5 - - Google Patents

Download PDF

Info

Publication number
JP2014524480A5
JP2014524480A5 JP2014527329A JP2014527329A JP2014524480A5 JP 2014524480 A5 JP2014524480 A5 JP 2014524480A5 JP 2014527329 A JP2014527329 A JP 2014527329A JP 2014527329 A JP2014527329 A JP 2014527329A JP 2014524480 A5 JP2014524480 A5 JP 2014524480A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
active agent
formulation
pharmaceutical
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014527329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524480A (ja
JP6169079B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/052304 external-priority patent/WO2013028989A1/en
Publication of JP2014524480A publication Critical patent/JP2014524480A/ja
Publication of JP2014524480A5 publication Critical patent/JP2014524480A5/ja
Application granted granted Critical
Publication of JP6169079B2 publication Critical patent/JP6169079B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014527329A 2011-08-24 2012-08-24 徐放のための活性剤の製剤 Active JP6169079B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161526940P 2011-08-24 2011-08-24
US61/526,940 2011-08-24
US201161551506P 2011-10-26 2011-10-26
US61/551,506 2011-10-26
PCT/US2012/052304 WO2013028989A1 (en) 2011-08-24 2012-08-24 Formulations of active agents for sustained release

Publications (3)

Publication Number Publication Date
JP2014524480A JP2014524480A (ja) 2014-09-22
JP2014524480A5 true JP2014524480A5 (enExample) 2015-10-15
JP6169079B2 JP6169079B2 (ja) 2017-07-26

Family

ID=47746903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014527329A Active JP6169079B2 (ja) 2011-08-24 2012-08-24 徐放のための活性剤の製剤

Country Status (7)

Country Link
US (2) US20130084277A1 (enExample)
EP (2) EP2747832A4 (enExample)
JP (1) JP6169079B2 (enExample)
CN (1) CN104023784B (enExample)
CA (1) CA2846209C (enExample)
HK (1) HK1199418A1 (enExample)
WO (1) WO2013028989A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
WO2015172046A1 (en) 2014-05-08 2015-11-12 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP7075757B2 (ja) * 2014-11-21 2022-05-26 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 制御放出および持続的放出のためのｅｌｐ融合タンパク質
WO2016130518A2 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN118078956A (zh) 2016-05-06 2024-05-28 免疫新炉有限公司 用于受控和持续释放的elp融合蛋白
CN119390817A (zh) * 2024-10-14 2025-02-07 华南理工大学 一种可编程的多重修饰长效缓释类弹性蛋白elp载体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
EP1896072A4 (en) * 2005-06-24 2013-01-09 Univ Duke SYSTEM FOR DIRECT HEALTH MANAGEMENT BASED ON HEAT-CONTROLLED BIOPOLYMERS
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
JP2009525946A (ja) * 2005-12-20 2009-07-16 デューク・ユニヴァーシティ 増強された薬理学的性質を有する活性物質を送達するための方法および組成物
US8178495B2 (en) * 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
US7709227B2 (en) * 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
CA2663047A1 (en) * 2006-09-06 2008-03-13 Phase Bioscience, Inc. Therapeutic elastin-like polypeptide (elp) fusion proteins
DK2155169T3 (en) * 2007-06-08 2016-06-13 Boehringer Ingelheim Int Formulation of nevirapine extended release
ES2672770T3 (es) * 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
US20110288001A1 (en) * 2008-12-18 2011-11-24 Homayoun Sadeghi Biologically active proteins activatable by peptidase
JP5801807B2 (ja) * 2009-08-14 2015-10-28 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 修飾された血管作動性腸管ペプチド
ES2669190T3 (es) * 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión

Similar Documents

Publication Publication Date Title
AU2023237119B2 (en) Buffered formulations of exendin (9-39)
ES2992698T3 (en) Combination of an insulin and a glp-1 agonist
US20250000933A1 (en) Terlipressin compositions and their methods of use
CA2814057C (en) Intravenous composition comprising paracetamol and ibuprofen
CA2846209C (en) Systemic sustained release formulation comprising elastin­like peptide repeating sequence and protein active agent
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
JP2018528242A (ja) 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法
JP2022502432A5 (enExample)
JP2020500864A5 (enExample)
CN110678194A (zh) 奥曲肽注射液
ES3062720T3 (en) Sublingual epinephrine tablets
JP2009506978A5 (enExample)
Hughes IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes
JP2020510028A5 (enExample)
JP2014502608A5 (enExample)
JP2008505087A5 (enExample)
EP4536691A1 (en) Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
CN114096269A (zh) 高浓度胰岛素制剂
JP2007513059A5 (enExample)
Kesavadev et al. Newer insulins on the horizon
HK40014065B (en) Terlipressin composition for use in treating ascites
HK40014065A (en) Terlipressin composition for use in treating ascites
Rubinstein Safety Of Nanomicellar Vasoactive Intestinal Peptide In Mice-Implications For Pulmonary Arterial Hypertension